Plus Therapeutics, Inc. – NASDAQ:PSTV
Plus Therapeutics stock price today
Plus Therapeutics stock price monthly change
Plus Therapeutics stock price quarterly change
Plus Therapeutics stock price yearly change
Plus Therapeutics key metrics
Market Cap | 6.30M |
Enterprise value | N/A |
P/E | -0.36 |
EV/Sales | N/A |
EV/EBITDA | 0.47 |
Price/Sales | N/A |
Price/Book | 1.13 |
PEG ratio | -0.01 |
EPS | -3.17 |
Revenue | 6.08M |
EBITDA | -10.91M |
Income | -11.77M |
Revenue Q/Q | 231.42% |
Revenue Y/Y | 657.65% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -179.44% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePlus Therapeutics stock price history
Plus Therapeutics stock forecast
Plus Therapeutics financial statements
| Jun 2023 | 1.85M | -1.48M | -79.94% |
|---|---|---|---|
| Sep 2023 | 1.24M | -3.21M | -259.6% |
| Dec 2023 | 1.31M | -3.81M | -290.18% |
| Mar 2024 | 1.67M | -3.26M | -194.45% |
| Dec 2023 | 1.31M | -3.81M | -290.18% |
|---|---|---|---|
| Mar 2024 | 1.67M | -3.26M | -194.45% |
| Sep 2025 | 750K | -2.93M | -391.84% |
| Dec 2025 | 250K | -3.47M | -1391.6% |
Analysts Price target
Financials & Ratios estimates
| 2023-08-03 | -1.91 | -53.95 |
|---|
| Jun 2023 | 14197000 | 11.53M | 81.25% |
|---|---|---|---|
| Sep 2023 | 13278000 | 10.65M | 80.25% |
| Dec 2023 | 11388000 | 12.73M | 111.84% |
| Mar 2024 | 5621000 | 10.45M | 186.05% |
| Jun 2023 | -2.77M | -11K | 961K |
|---|---|---|---|
| Sep 2023 | -2.39M | -10K | 2.52M |
| Dec 2023 | -1.88M | -42K | -529K |
| Mar 2024 | -4.51M | -364K | -776K |
Plus Therapeutics alternative data
| Aug 2023 | 17 |
|---|---|
| Sep 2023 | 17 |
| Oct 2023 | 17 |
| Nov 2023 | 17 |
| Dec 2023 | 17 |
| Jan 2024 | 17 |
| Feb 2024 | 17 |
| Mar 2024 | 20 |
| Apr 2024 | 20 |
| May 2024 | 20 |
| Jun 2024 | 20 |
| Jul 2024 | 20 |
Plus Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Jun 2023 | 1000 | 0 |
| Sep 2023 | 26993 | 0 |
| Nov 2023 | 24594 | 2068 |
| May 2024 | 48285 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | PETERSEN GREG director | Common Stock | 12,255 | $2.04 | $25,000 | ||
Purchase | SIMS ANDREW JOHN HUGH MACINTYRE officer: Chief Fi.. | Common Stock | 4,902 | $2.04 | $10,000 | ||
Purchase | CLOWES HOWARD director | Common Stock | 9,804 | $2.04 | $20,000 | ||
Purchase | HAWKINS RICHARD J director | Common Stock | 4,902 | $2.04 | $10,000 | ||
Purchase | LENK ROBERT P director | Common Stock | 4,167 | $2.04 | $8,501 | ||
Purchase | HEDRICK MARC H director, officer.. | Common Stock | 12,255 | $2.04 | $25,000 | ||
Sale | HEDRICK MARC H director, officer.. | Common Stock | 2,068 | $1.96 | $4,053 | ||
Purchase | LENK ROBERT P director | Common Stock | 1,000 | $1.95 | $1,950 | ||
Purchase | LENK ROBERT P director | Common Stock | 1,000 | $1.77 | $1,770 | ||
Purchase | LENK ROBERT P director | Common Stock | 4,000 | $1.43 | $5,720 |
| Patent |
|---|
Application Filling date: 17 May 2022 Issue date: 1 Sep 2022 |
Application Filling date: 6 Aug 2018 Issue date: 17 Dec 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 15 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 5 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 31 Oct 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 14 Aug 2023 | Q2 2023 Earnings Call Transcript |
-
What's the price of Plus Therapeutics stock today?
One share of Plus Therapeutics stock can currently be purchased for approximately $0.52.
-
When is Plus Therapeutics's next earnings date?
Unfortunately, Plus Therapeutics's (PSTV) next earnings date is currently unknown.
-
Does Plus Therapeutics pay dividends?
No, Plus Therapeutics does not pay dividends.
-
How much money does Plus Therapeutics make?
Plus Therapeutics has a market capitalization of 6.30M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 2093.3% to 4.91M US dollars. Plus Therapeutics made a loss 13.32M US dollars in net income (profit) last year or -$53.95 on an earnings per share basis.
-
What is Plus Therapeutics's stock symbol?
Plus Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "PSTV".
-
What is Plus Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Plus Therapeutics?
Shares of Plus Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Plus Therapeutics's key executives?
Plus Therapeutics's management team includes the following people:
- Dr. Marc H. Hedrick M.D. Pres, Chief Executive Officer & Director(age: 62, pay: $838,430)
- Mr. Andrew J. Sims Vice President of Fin. & Chief Financial Officer(age: 52, pay: $376,590)
-
How many employees does Plus Therapeutics have?
As Jul 2024, Plus Therapeutics employs 20 workers.
-
When Plus Therapeutics went public?
Plus Therapeutics, Inc. is publicly traded company for more then 24 years since IPO on 11 Jul 2001.
-
What is Plus Therapeutics's official website?
The official website for Plus Therapeutics is plustherapeutics.com.
-
Where are Plus Therapeutics's headquarters?
Plus Therapeutics is headquartered at 4200 Marathon Boulevard, Austin, TX.
-
How can i contact Plus Therapeutics?
Plus Therapeutics's mailing address is 4200 Marathon Boulevard, Austin, TX and company can be reached via phone at +7 372557194.
Plus Therapeutics company profile:
Plus Therapeutics, Inc.
plustherapeutics.comNASDAQ
20
Biotechnology
Healthcare
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Austin, TX 78756
CIK: 0001095981
ISIN: US72941H5090
CUSIP: 72941H400
